drugset / Trial / NCT07428616

A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

NCT07428616

Phase 2 Recruiting 100 enrolled Exelixis
NaSingle-groupOpen-labelTreatment

Summary

The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.

Timeline

Start
2026-05-21
Primary completion
2028-02-29
Completion
2029-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Zanzalintinib Small molecule

Indications